How a Popular Weight-Loss Drug Saved Rosie O’Donnell’s Life
New York, Friday, 24 July 2026.
Rosie O’Donnell credited the diabetes drug Mounjaro for saving her life, advocating for lower pharmaceutical prices over celebrity endorsement deals after her 60-pound weight loss.
A Personal Transformation and a ‘Miracle’ Drug
The 64-year-old comedian and actress Rosie O’Donnell has sparked a fresh conversation around GLP-1 receptor agonists after revealing that the diabetes medication Mounjaro “saved my life” [1][2][4]. O’Donnell began taking the drug, which is manufactured by Eli Lilly (NYSE: LLY) [GPT], approximately three years ago in 2023 following a type 2 diabetes diagnosis [1][5][6]. Over this three-year period, O’Donnell experienced a gradual weight loss of about 60 pounds (27.22 kg), shedding weight at a highly controlled pace of 1 to 2 pounds (0.45 to 0.91 kg) per month [1][2][4][5][6]. This steady regimen equates to an average loss of 20 pounds per year, a slow-and-steady approach she has openly embraced [1][3][5].
Addressing Trauma and the Food Noise
O’Donnell has been highly transparent about her journey, stating that she was “stunned” by how the medication effectively “quieted the food noise” that had plagued her for decades [1][4][5][6]. She has long connected her struggles with obesity and weight to the profound grief and trauma she experienced following the 1973 death of her mother, Roseann O’Donnell, when Rosie was just 10 years old [1][2][4]. Though she previously underwent vertical gastric sleeve surgery to address her weight, she credits the biological mechanism of the GLP-1 drug for finally delivering sustainable physical and mental relief [4][6].
The High Cost of Aesthetic and Medical Autonomy
Her dramatic physical transformation eventually led O’Donnell to address the resulting excess skin and “marionette lines” on her face [1][6]. Last May, she underwent a deep plane facelift costing $90,000—a major financial decision she deliberated on for six months [1][5][6]. While she initially hesitated due to feminist concerns regarding conforming to the “male gaze,” O’Donnell ultimately concluded that the true essence of feminism lies in the autonomy to decide what to do with one’s own body [5][6]. She was supported through the recovery process by actress Ricki Lake, who acted as her “coach,” even as her youngest child, Clay, questioned how the cosmetic procedure aligned with her legacy [1][5].
Public Advocacy and Corporate Responsibility
The financial realities of both the surgery and the weight-loss medication have also prompted O’Donnell to speak out on drug pricing. She expressed a strong desire to do commercials for Mounjaro, on the condition that the pharmaceutical manufacturers drop the retail price of the drug instead of paying her a celebrity endorsement fee [2]. This public stance highlights the broader economic debate surrounding GLP-1 drugs, which carry high out-of-pocket costs for many patients despite generating billions in revenue for pharmaceutical giants like Eli Lilly and Novo Nordisk (NYSE: NVO) [GPT].
The Broader Cultural and Economic GLP-1 Phenomenon
O’Donnell is far from the only high-profile figure keeping GLP-1 medications in the cultural spotlight. Celebrities such as Oprah Winfrey, Whoopi Goldberg, and Meghan Trainor have also publicly shared their positive experiences using Mounjaro or similar drugs for weight management [4][6]. However, the trend remains highly polarized; model Ashley Graham has criticized the widespread use of these drugs as a setback for the body positivity movement [4]. Furthermore, other public figures have highlighted the potential physical toll of the medications, with Mayim Bialik and Jenny Mollen reporting severe adverse side effects, including intense gastrointestinal distress and hormonal fluctuations, in June 2026 [2][4].
A New Chapter in the Public Eye
Despite the ongoing debates, O’Donnell is currently channeling her renewed energy into her career. Her new one-woman show, Common Knowledge, officially opened this week on July 22, 2026, at the Daryl Roth Theater in New York City [1][3]. Photographed looking healthy and confident during her public appearances in New York, O’Donnell is also set to appear on the cover of the upcoming August 3, 2026 issue of PEOPLE magazine [1][2]. For the broader market, her story serves as a vivid case study of how medical advancements in weight management are reshaping not only individual lives but also the global healthcare economy [GPT].